BMJ Rapid Recommendation: Plasma exchange and glucocorticoids tapering scheme in patients with ANCA-associated vasculitis

Published by Linan Zeng on Oct 24, 2022

View

Disclaimer

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 10.1

Population
Patients with AAV (Overall)
Intervention
Plasma exchange + standard care
Comparator
Standard care
Outcomes

PICO 10.2

Population
Patients with AAV and with low risk of developing ESKD (serum creatinine ≤ 200 µmol/l)
Intervention
Plasma exchange + standard care
Comparator
Standard care
Outcomes

PICO 10.3

Population
Patients with AAV and with low-moderate risk of developing ESKD (serum creatinine 200-300 µmol/l)
Intervention
Plasma exchange + standard care
Comparator
Standard care
Outcomes

PICO 10.4

Population
Patients with AAV and with moderate-high risk of developing ESKD (serum creatinine 300-500 µmol/l)
Intervention
Plasma exchange + standard care
Comparator
Standard care
Outcomes

PICO 10.5

Population
Patients with AAV and with high risk of developing ESKD (serum creatinine > 500 µmol/l or requiring dialysis)
Intervention
Plasma exchange + standard care
Comparator
Standard care
Outcomes

PICO 20.1

Population
Patients with ANCA associated vasculitis and pulmonary haemorrhage
Intervention
Plasma Exchange + standard care
Comparator
Standard Care
Outcomes

PICO 30.1

Population
ANCA-associated vasculitis
Intervention
Reduced-dose regimen of glucocorticoids
Comparator
Standard-dose regimen of glucocorticoids
Outcomes

PICO 30.2

Population
ANCA-associated vasculitis
Intervention
Reduced-dose regimen of glucocorticoids
Comparator
Standard-dose regimen of glucocorticoids
Outcomes